Endo International (LTS:0Y5F) ROCE % : -207.72% (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Endo International ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Endo International's annualized ROCE % for the quarter that ended in Dec. 2023 was -207.72%.

Endo International ROCE % Historical Data

The historical data trend for Endo International's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Endo International ROCE % Chart

Endo International Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

2.41

6.35

0.21

-41.58

-49.47

Endo International Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial															-18.14	0.26	2.82	-1.40	-207.72

Endo International ROCE % Calculation

Endo International's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-2390.933	/	( ( (5757.937 - 689.627)	+	(5137.294 - 538.794) )	/ 2 )
	=	-2390.933	/	( (5068.31	+	4598.5)	/ 2 )
	=	-2390.933	/	4833.405
	=	-49.47 %

Endo International's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	-9648.064	/	( ( (5255.795 - 564.632)	+	(5137.294 - 538.794) )	/ 2 )
	=	-9648.064	/	( ( 4691.163	+	4598.5 )	/ 2 )
	=	-9648.064	/	4644.8315
	=	-207.72 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

Endo International (LTS:0Y5F) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Endo International ROCE % Related Terms

Thank you for viewing the detailed overview of Endo International's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Endo International (LTS:0Y5F) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Endo International PLC (LTS:0Y5F) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

ENDPQ:USA EO7:Germany

Address

Simmonscourt Road, Ballsbridge, First Floor, Minerva House, Dublin, IRL, 4

Website

https://www.endo.com

Endo International PLC is a specialty pharmaceutical company with a considerable presence in pain management, urology, orthopedics, endocrinology, bariatrics, and others. It operates in four segments: Branded Pharmaceuticals, Sterile Injectables, Generic Pharmaceuticals, and International Pharmaceuticals. The company generates maximum revenue from the Branded Pharmaceuticals segment. Some of its products include XIAFLEX, SUPPRELIN, PERCOCET, TESTOPEL, VASOSTRICT, ADRENALIN, and APLISOL.

Endo International (LTS:0Y5F) Headlines

No Headlines